Treatment News : Rates of Failure in HIV Drugs Vary Widely in Poorer Nations

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 14, 2013

Rates of Failure in HIV Drugs Vary Widely in Poorer Nations

There is a vast range in outcomes of success at suppressing HIV with antiretroviral (ARV) treatment among people taking the drugs in resource-limited nations, aidsmap reports. Publishing their findings in Clinical Infectious Diseases, an international group of researchers conducted a cross-sectional study between Burkina Faso, Cameroon, Côte d’Ivoire, Senegal, Togo, Thailand and Vietnam in order to determine the rate of virologic failure and drug resistance mutations (DRMs) among HIV-positive people receiving treatment under the World Health Organization’s protocol for both delivery and monitoring of treatment.

Between 2009 and 2011, the investigators recruited 2,060 adults who were attending treatment centers 10 to 14 months after beginning ARVs (called the M12 group) and 1,875 adults in the 22 to 26 month range (the M24 group).

The average rate of virologic failure was 11.1 percent for the M12 group and 12.4 percent for the M24 group. The respective rates of drug-resistant virus among those in the groups who had virologic failure were 71 percent and 86.1 percent for the M12 and M24 group. Virologic failure rates ranged between 2.9 percent and 20.6 percent in the M12 group and 3.7 percent to 26 percent in the M24 group. For the most part, DRMs were linked to ARV regimens, but several of the participants racked up DRMs to drugs they had not received.

The study authors concluded that proper management of ARV programs is “critical to improve treatment outcomes in resource-limited countries.”

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, virologic failure, suppressed viral load, aidsmap, Burkina Faso, Cameroon, Côte d’Ivoire, Senegal, Togo, Thailand, Vietnam, drug resistance mutations, DRM.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 1 (of 1 total)    

david, kampala, 2013-11-15 04:21:17
what do u expect when at time they give cotrimoxazole for some months

comments 1 - 1 (of 1 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.